ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Aclaris buys kinase-focused Confluence

by Lisa M. Jarvis
August 20, 2017 | APPEARED IN VOLUME 95, ISSUE 33

Confluence Life Sciences, a St. Louis-based developer of kinase inhibitors for cancer and other diseases, has been acquired by Aclaris Therapeutics for $10 million in cash and stock. Dermatology-focused Aclaris says the deal adds a preclinical inhibitor of the MK2 pathway, implicated in arthritis and other autoimmune diseases, as well as earlier-stage molecules targeting other inflammation pathways. Confluence was founded by former Pfizer scientists after layoffs at the big pharma firm’s St. Louis site in 2009.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment